{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:49:15Z","timestamp":1793875755635,"version":"4.7.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.biopha.2018.02.038","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T08:32:13Z","timestamp":1518769933000},"page":"335-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"special_numbering":"C","title":["Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR"],"prefix":"10.1016","volume":"100","author":[{"given":"Imran Shair","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(92)92404-L","article-title":"P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site","volume":"188","author":"Ferry","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5191","key":"10.1016\/j.biopha.2018.02.038_bib0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/222385a0","article-title":"Platinum compounds: a new class of potent antitumour agents","volume":"222","author":"Rosenberg","year":"1969","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu. Rev. Biochem."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2018.02.038_bib0020","first-page":"100","article-title":"Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells","volume":"24","author":"M\u00fcller","year":"1996","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcp.2007.03.028","article-title":"C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells","volume":"74","author":"Bram","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2018.02.038_bib0030","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1593\/neo.91314","article-title":"Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance","volume":"11","author":"Bram","year":"2009","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2217\/pgs.12.213","article-title":"Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy","volume":"14","author":"Weng","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0040","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3892\/or.2014.3702","article-title":"Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer","volume":"33","author":"Zhang","year":"2015","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jmb.2008.11.027","article-title":"Translational coupling controls expression and function of the DrrAB drug efflux pump","volume":"385","author":"Pradhan","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1152\/physiol.00046.2006","article-title":"Structure and function of ABC transporters","volume":"22","author":"Linton","year":"2007","journal-title":"Physiology"},{"key":"10.1016\/j.biopha.2018.02.038_bib0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0076-6879(05)00024-8","article-title":"The genetics of ATP-binding cassette transporters","volume":"400","author":"Dean","year":"2005","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","article-title":"Modulation of human BCRP (ABCG2) activity by anti-HIV drugs","volume":"59","author":"Weiss","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2018.02.038_bib0070","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"42","author":"Dean","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2018.02.038_bib0075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nature05630","article-title":"Multiple molecular mechanisms for multidrug resistance transporters","volume":"446","author":"Higgins","year":"2007","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.biopha.2018.02.038_bib0080","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/glia.20725","article-title":"Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection","volume":"56","author":"Ronaldson","year":"2008","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/pr.58.2.3","article-title":"Multidrug resistance-associated proteins: expression and function in the central nervous system","volume":"58","author":"Dallas","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2018.02.038_bib0090","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","article-title":"Intestinal drug transporters: an overview","volume":"65","author":"Estudante","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"16","key":"10.1016\/j.biopha.2018.02.038_bib0095","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/glia.20725","article-title":"Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection","volume":"56","author":"Ronaldson","year":"2008","journal-title":"Glia"},{"issue":"9","key":"10.1016\/j.biopha.2018.02.038_bib0100","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s11095-009-9930-2","article-title":"Inner blood-retinal barrier transporters: role of retinal drug delivery","volume":"26","author":"Hosoya","year":"2009","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2018.02.038_bib0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.02.038_bib0120","series-title":"International Review of Cell and Molecular Biology","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1937-6448(10)80005-X","article-title":"Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy","author":"Weiss","year":"2010"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.63.1.65","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors","volume":"63","author":"Wang","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2018.02.038_bib0130","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1124\/dmd.107.017723","article-title":"P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution","volume":"11","author":"Shaik","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2018.02.038_bib0135","series-title":"Pharmacogenetics of Drug Transporters, Pharmacogenetics and Individualized Therapy","first-page":"101","author":"Meyer zu Schwabedissen","year":"2012"},{"key":"10.1016\/j.biopha.2018.02.038_bib0140","first-page":"219","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.107.127704","article-title":"Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells","volume":"324","author":"Shen","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"16","key":"10.1016\/j.biopha.2018.02.038_bib0150","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2007.14.9807","article-title":"Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer","volume":"26","author":"Lhomm\u00e9","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2018.02.038_bib0155","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00280-009-0925-9","article-title":"A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen","volume":"64","author":"Ruff","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2018.02.038_bib0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.biopha.2018.02.038_bib0165","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0959-8049(96)00091-3","article-title":"Clinical trials of p-glycoprotein reversal in solid tumours","volume":"32","author":"Ferry","year":"1996","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2018.02.038_bib0170","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bcp.2007.12.001","article-title":"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1\u00ae","volume":"75","author":"Robey","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0175","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3390\/molecules20022931","article-title":"Inhibitory effects of neochamaejasmin B on P-glycoprotein in MDCK-hMDR1 cells and molecular docking of NCB binding in P-glycoprotein","volume":"20","author":"Pan","year":"2015","journal-title":"Molecules"},{"issue":"48","key":"10.1016\/j.biopha.2018.02.038_bib0180","doi-asserted-by":"crossref","first-page":"84559","DOI":"10.18632\/oncotarget.19187","article-title":"Novel strategies to prevent the development of multidrug resistance (MDR) in cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.biopha.2018.02.038_bib0185","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0959-8049(02)00490-2","article-title":"MDR1 inhibition: less resistance or less relevance?","volume":"38","author":"Garraway","year":"2002","journal-title":"Eur. J. Cancer (Oxf. Engl.: 1990)"},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","article-title":"The role of ABC transporters in clinical practice","volume":"8","author":"Leonard","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2018.02.038_bib0195","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0076-6879(05)00024-8","article-title":"The genetics of ATP\u2010binding cassette transporters","author":"Dean","year":"2005"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","article-title":"Modulation of human BCRP (ABCG2) activity by anti-HIV drugs","volume":"59","author":"Weiss","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0205","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/jpet.111.186916","article-title":"Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier","volume":"340","author":"Robillard","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0215","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2005.11.036","article-title":"Cellular and virological mechanisms of HBV drug resistance","volume":"44","author":"Locarnini","year":"2006","journal-title":"J. Hepatol."},{"issue":"47","key":"10.1016\/j.biopha.2018.02.038_bib0220","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.biopha.2018.02.038_bib0225","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/15216540701736285","article-title":"Role of the MRP1\/ABCC1 multidrug transporter protein in cancer","volume":"59","author":"Munoz","year":"2007","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","article-title":"ABCG2: determining its relevance in clinical drug resistance","volume":"26","author":"Robey","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biopha.2018.02.038_bib0235","series-title":"Stem Cell Biology in Health and Disease","first-page":"385","article-title":"Potential molecular therapeutic targets in cancer stem\/progenitor cells: are ATP-binding cassette membrane transporters appropriate targets to eliminate cancer-initiating cells?","author":"Mimeault","year":"2010"},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0240","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10863-007-9122-x","article-title":"ABCG transporters: structure, substrate specificities and physiological roles","volume":"39","author":"Velamakanni","year":"2007","journal-title":"J. Bioenergy Biomembr."},{"issue":"6","key":"10.1016\/j.biopha.2018.02.038_bib0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nsmb.3216","article-title":"Mechanistic diversity in ATP-binding cassette (ABC) transporters","volume":"23","author":"Locher","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6282","key":"10.1016\/j.biopha.2018.02.038_bib0250","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/346362a0","article-title":"Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport","volume":"346","author":"Hyde","year":"1990","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.biopha.2018.02.038_bib0255","first-page":"5130","article-title":"Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione","volume":"58","author":"Loe","year":"1998","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0260","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1432-1033.1997.00130.x","article-title":"Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities","volume":"250","author":"Shapiro","year":"1997","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0270","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1046\/j.1432-1327.1999.00098.x","article-title":"Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone","volume":"259","author":"Shapiro","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.biopha.2018.02.038_bib0275","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1161\/ATVBAHA.117.309574","article-title":"ABCA8 regulates cholesterol efflux and high-density lipoprotein cholesterol levels","volume":"11","author":"Trigueros-Motos","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Biomembr."},{"issue":"11","key":"10.1016\/j.biopha.2018.02.038_bib0285","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.107.016352","article-title":"Evaluation of the role of breast cancer resistance protein (BCRP\/ABCG2) and multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one)","volume":"35","author":"Mizuno","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.biopha.2018.02.038_bib0290","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/00002030-200107270-00004","article-title":"P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?","volume":"15","author":"Jones","year":"2001","journal-title":"Aids"},{"issue":"11","key":"10.1016\/j.biopha.2018.02.038_bib0295","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1124\/dmd.111.041228","article-title":"Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0300","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/17425255.2016.1168804","article-title":"ABC transporters at the blood\u2013brain barrier","volume":"12","author":"Mahringer","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2018.02.038_bib0305","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1038\/tp.2012.115","article-title":"ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression","volume":"2","author":"Singh","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-5793(96)01478-0","article-title":"Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters","volume":"402","author":"Tusn\u00e1dy","year":"1997","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0315","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"ABC multidrug transporters: structure, function and role in chemoresistance","volume":"9","author":"Sharom","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.biopha.2018.02.038_bib0320","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI928","article-title":"Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA","volume":"101","author":"Evers","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0325","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1054\/bjoc.2000.1262","article-title":"Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export","volume":"83","author":"Evers","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2018.02.038_bib0330","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091941","article-title":"The ABCC6 transporter: a new player in biomineralization","volume":"18","author":"Favre","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0335","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","article-title":"Human ATP-binding cassette (ABC) transporter family","volume":"3","author":"Vasiliou","year":"2009","journal-title":"Hum. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0340","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-3565(24)35293-0","article-title":"Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4","volume":"292","author":"Hochman","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2018.02.038_bib0345","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"42","author":"Dean","year":"2001","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0350","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/10717544.2017.1381199","article-title":"A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP","volume":"24","author":"Zhang","year":"2017","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0355","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/BJ20040791","article-title":"Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2)","volume":"385","author":"Janvilisri","year":"2005","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.biopha.2018.02.038_bib0360","first-page":"935","article-title":"Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918","volume":"7","author":"Maliepaard","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2018.02.038_bib0365","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.biopha.2018.02.038_bib0370","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/00001756-200211150-00014","article-title":"Localisation of breast cancer resistance protein in microvessel endothelium of human brain","volume":"13","author":"Cooray","year":"2002","journal-title":"NeuroReport"},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0375","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00424-006-0047-8","article-title":"The ABCA subfamily\u2014gene and protein structures, functions and associated hereditary diseases","volume":"453","author":"Albrecht","year":"2007","journal-title":"Pflug. Arch."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0380","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","article-title":"Mammalian ABC transporters in health and disease","volume":"71","author":"Borst","year":"2002","journal-title":"Annu. Rev. Biochem."},{"issue":"14 Pt. 1","key":"10.1016\/j.biopha.2018.02.038_bib0385","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1158\/1078-0432.CCR-05-2587","article-title":"ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia","volume":"12","author":"Steinbach","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2018.02.038_bib0390","doi-asserted-by":"crossref","DOI":"10.1101\/gr.184901","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2018.02.038_bib0395","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0169-409X(99)00026-5","article-title":"Involvement of multiple transporters in the oral absorption of nucleoside analogues","volume":"39","author":"Balimane","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"22","key":"10.1016\/j.biopha.2018.02.038_bib0400","first-page":"5130","article-title":"Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione","volume":"58","author":"Loe","year":"1998","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2018.02.038_bib0405","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.biopha.2018.02.038_bib0410","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-11-0221","article-title":"ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients","volume":"71","author":"Wilson","year":"2011","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0415","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.vascn.2012.02.002","article-title":"Determining P-glycoprotein\u2013drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers","volume":"65","author":"Melchior","year":"2012","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"18","key":"10.1016\/j.biopha.2018.02.038_bib0420","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/j.1742-4658.2011.08235.x","article-title":"Multidrug resistance proteins (MRPs\/ABCCs) in cancer chemotherapy and genetic diseases","volume":"278","author":"Chen","year":"2011","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0425","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00424-006-0114-1","article-title":"ABCC10, ABCC11, and ABCC12","volume":"453","author":"Kruh","year":"2007","journal-title":"Pflug. Arch."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0430","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2004.06.026","article-title":"Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells","volume":"6","author":"Szak\u00e1cs","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: a perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2018.02.038_bib0440","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10611860310001648248","article-title":"Classification analysis of P-glycoprotein substrate specificity","volume":"11","author":"Remigijus Didziapetris","year":"2003","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0445","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2012.01.005","article-title":"Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance","volume":"15","author":"Shukla","year":"2012","journal-title":"Drug Resist. Updates"},{"issue":"10","key":"10.1016\/j.biopha.2018.02.038_bib0450","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1940-6207.CAPR-10-0030","article-title":"Colon tumor cell growth\u2013inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition","volume":"3","author":"Tinsley","year":"2010","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.02.038_bib0455","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","article-title":"Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs","volume":"11","author":"Krishna","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0460","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-10-1725","article-title":"A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer","volume":"17","author":"Kelly","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.02.038_bib0465","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1349-7006.1989.tb01688.x","article-title":"Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies","volume":"80","author":"Tsuruo","year":"1989","journal-title":"Jpn. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0470","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/83.2.105","article-title":"Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration","volume":"83","author":"Pennock","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2018.02.038_bib0475","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2018.02.038_bib0480","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1553-2712.2008.00088.x","article-title":"Verapamil toxicity dysregulates the phosphatidylinositol 3-kinase pathway","volume":"15","author":"Bechtel","year":"2008","journal-title":"Acad. Emerg. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0485","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mt.2011.230","article-title":"Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer","volume":"20","author":"Koski","year":"2012","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0490","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control: J. Moffitt Cancer Cent."},{"issue":"8","key":"10.1016\/j.biopha.2018.02.038_bib0495","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1995.13.8.1985","article-title":"Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy","volume":"13","author":"Wilson","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2018.02.038_bib0500","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1200\/JCO.2000.18.9.1837","article-title":"P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein\u2013positive acute myeloid leukemia","volume":"18","author":"Tidefelt","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0505","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/1078-0432.CCR-0914-3","article-title":"VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein","volume":"10","author":"Minderman","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0510","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF00686322","article-title":"Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype","volume":"30","author":"te Boekhorst","year":"1992","journal-title":"Cancer Chemother. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2018.02.038_bib0515","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/0277-5379(91)90435-G","article-title":"Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A","volume":"27","author":"Twentyman","year":"1991","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0520","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00686321","article-title":"Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor","volume":"30","author":"Friche","year":"1992","journal-title":"Cancer Chemother. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0525","first-page":"1221","article-title":"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance","volume":"7","author":"Advani","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0530","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.1996.14.2.610","article-title":"Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer","volume":"14","author":"Boote","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.biopha.2018.02.038_bib0535","first-page":"18","article-title":"Defeating drug resistance in cancer","volume":"6","author":"Gottesman","year":"2006","journal-title":"Discov. Med."},{"key":"10.1016\/j.biopha.2018.02.038_bib0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updates"},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0545","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","article-title":"The role of ABC transporters in clinical practice","volume":"8","author":"Leonard","year":"2003","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0550","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0889-8588(18)30097-2","article-title":"MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors","volume":"9","author":"Lum","year":"1995","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"16","key":"10.1016\/j.biopha.2018.02.038_bib0555","first-page":"3944","article-title":"P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies","volume":"59","author":"Wandel","year":"1999","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2018.02.038_bib0560","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1200\/JCO.1998.16.9.2964","article-title":"Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP","volume":"16","author":"Rowinsky","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2018.02.038_bib0565","first-page":"802","article-title":"The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite","volume":"26","author":"Fischer","year":"1998","journal-title":"Drug Metab. Dispos."},{"issue":"16","key":"10.1016\/j.biopha.2018.02.038_bib0570","first-page":"3944","article-title":"P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies","volume":"59","author":"Wandel","year":"1999","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0575","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(24)34974-2","article-title":"Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities","volume":"290","author":"Dantzig","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0580","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1021\/bi051276s","article-title":"Nucleotide-binding sites of the heterodimeric LmrCD ABC-multidrug transporter of Lactococcus lactis are asymmetric","volume":"45","author":"Lubelski","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2018.02.038_bib0585","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2407-8-51","article-title":"Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)","volume":"8","author":"Tang","year":"2008","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0590","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1208\/s12248-009-9118-z","article-title":"Structure-activity relationships of tariquidar analogs as multidrug resistance modulators","volume":"11","author":"Pajeva","year":"2009","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0595","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \"specific\" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0600","first-page":"554","article-title":"3D-QSAR and contour map analysis of tariquidar analogues as multidrug resistance protein-1 (MRP1) inhibitors","volume":"7","author":"Kakarla","year":"2016","journal-title":"Int. J. Pharm. Sci. Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1006487003814","article-title":"Development of multidrug-resistance convertors: sense or nonsense?","volume":"18","author":"van Zuylen","year":"2000","journal-title":"Invest. New Drugs"},{"issue":"11","key":"10.1016\/j.biopha.2018.02.038_bib0610","first-page":"2964","article-title":"Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance","volume":"60","author":"Newman","year":"2000","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2018.02.038_bib0615","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2174\/187152012802650011","article-title":"Polyphenols counteract tumor cell chemoresistance conferred by multidrug resistance proteins","volume":"12","author":"Michalak","year":"2012","journal-title":"Anticancer. Agents Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2018.02.038_bib0620","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/md12073818","article-title":"A pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells","volume":"12","author":"Huang","year":"2014","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0625","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/md12010525","article-title":"Marine natural products with P-glycoprotein inhibitor properties","volume":"12","author":"Lopez","year":"2014","journal-title":"Mar. Drugs"},{"issue":"15","key":"10.1016\/j.biopha.2018.02.038_bib0630","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1016\/j.bmc.2017.06.015","article-title":"Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors","volume":"25","author":"Pan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2018.02.038_bib0635","first-page":"1","article-title":"Ethyl lucidenates A reverses P-glycoprotein mediated vincristine resistance in K562\/A02 cells","author":"Li","year":"2017","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.biopha.2018.02.038_bib0640","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biopha.2017.07.126","article-title":"A novel ventricular restraint device (ASD) repetitively deliver Salvia miltiorrhiza to epicardium have good curative effects in heart failure management","volume":"95","author":"Naveed","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.02.038_bib0645","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.biopha.2017.10.016","article-title":"TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters","volume":"96","author":"Li","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.02.038_bib0650","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.taap.2017.10.018","article-title":"ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells","volume":"337","author":"Mirzaei","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"36","key":"10.1016\/j.biopha.2018.02.038_bib0655","doi-asserted-by":"crossref","first-page":"60453","DOI":"10.18632\/oncotarget.19728","article-title":"Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles","volume":"8","author":"Zou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2018.02.038_bib0660","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fonc.2014.00002","article-title":"Small and innovative molecules as new strategy to revert MDR","volume":"4","author":"Zinzi","year":"2014","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0665","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12366","article-title":"Visfatin mediates doxorubicin resistance in human non\u2013small-cell lung cancer via Akt-mediated up-regulation of ABCC1","volume":"50","author":"Cao","year":"2017","journal-title":"Cell Prolif."},{"key":"10.1016\/j.biopha.2018.02.038_bib0670","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2017.08.035","article-title":"Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines","volume":"409","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0675","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jps.20780","article-title":"Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro\/in vivo case studies","volume":"96","author":"Constantinides","year":"2007","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2018.02.038_bib0680","first-page":"1195","article-title":"Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin","volume":"32","author":"Riehm","year":"1972","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0685","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/17425255.2.5.733","article-title":"Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding","volume":"2","author":"Seelig","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"10","key":"10.1016\/j.biopha.2018.02.038_bib0690","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1023\/A:1015000503629","article-title":"Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)","volume":"16","author":"Dintaman","year":"1999","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0695","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-3659(03)00163-9","article-title":"Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines","volume":"90","author":"Lo","year":"2003","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0700","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/jpet.102.043307","article-title":"Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells","volume":"304","author":"Batrakova","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4\u20135","key":"10.1016\/j.biopha.2018.02.038_bib0705","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0928-0987(02)00055-6","article-title":"Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers","volume":"16","author":"Rege","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.02.038_bib0710","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-3835(99)00355-9","article-title":"Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx","volume":"149","author":"Yamazaki","year":"2000","journal-title":"Cancer Lett."},{"issue":"23","key":"10.1016\/j.biopha.2018.02.038_bib0715","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1016\/j.biomaterials.2006.03.033","article-title":"In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan","volume":"27","author":"F\u00f6ger","year":"2006","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.biopha.2018.02.038_bib0720","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00137696-200604040-00008","article-title":"Polymeric efflux pump inhibitors in oral drug delivery","volume":"4","author":"Bernkop-Schn\u00fcrch","year":"2006","journal-title":"Am. J. Drug Deliv."},{"issue":"21\u201322","key":"10.1016\/j.biopha.2018.02.038_bib0725","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2009.07.010","article-title":"Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation","volume":"14","author":"Bansal","year":"2009","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0730","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.02.038_bib0735","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2006.01.020","article-title":"Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies","volume":"313","author":"Shen","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.02.038_bib0740","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2005.11.011","article-title":"Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine","volume":"111","author":"Werle","year":"2006","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0745","first-page":"319","article-title":"Lipid excipients Peceol and Gelucire 44\/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells","volume":"10","author":"Sachs-Barrable","year":"2007","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0750","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02976620","article-title":"Recent progress in drug delivery systems for anticancer agents","volume":"25","author":"Kim","year":"2002","journal-title":"Arch. Pharmacal Res."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.02.038_bib0755","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2006.03.045","article-title":"Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux","volume":"320","author":"Chavanpatil","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0760","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1021\/mp070024d","article-title":"Surfactant\u2013polymer nanoparticles overcome P-glycoprotein-mediated drug efflux","volume":"4","author":"Chavanpatil","year":"2007","journal-title":"Mol. Pharm."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.02.038_bib0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(01)00406-0","article-title":"Effect of PSC 833 liposomes and intralipid on the transport of epirubicin in Caco-2 cells and rat intestines","volume":"76","author":"Lo","year":"2001","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.biopha.2018.02.038_bib0770","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1368-7646(03)00082-7","article-title":"Liposome-based approaches to overcome anticancer drug resistance","volume":"6","author":"Mamot","year":"2003","journal-title":"Drug Resist. Updates"},{"issue":"11","key":"10.1016\/j.biopha.2018.02.038_bib0775","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/sj.bjc.6601856","article-title":"Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer","volume":"90","author":"Danson","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0780","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0927-7765(99)00064-8","article-title":"Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials","volume":"16","author":"Alakhov","year":"1999","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0785","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejpb.2008.08.015","article-title":"Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies","volume":"71","author":"Nornoo","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0790","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0795","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2011.01.024","article-title":"Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro","volume":"152","author":"Kievit","year":"2011","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0800","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/nnm.12.216","article-title":"Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma","volume":"9","author":"Yang","year":"2014","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2018.02.038_bib0805","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0927-7765(99)00080-6","article-title":"Poly(ethylene glycol)\u2013polyethyleneimine NanoGel\u2122 particles: novel drug delivery systems for antisense oligonucleotides","volume":"16","author":"Vinogradov","year":"1999","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"6","key":"10.1016\/j.biopha.2018.02.038_bib0810","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1211\/0022357011776126","article-title":"Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance","volume":"53","author":"Liu","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2018.02.038_bib0815","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.biopha.2018.02.038_bib0820","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2006.09.007","article-title":"Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer","volume":"116","author":"Wong","year":"2006","journal-title":"J. Control. Release"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217370166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217370166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:07:23Z","timestamp":1761242843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217370166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":164,"alternative-id":["S0753332217370166"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.02.038","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}